Bausch + Lomb/$BLCO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Bausch + Lomb
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Ticker
$BLCO
Sector
Primary listing
NYSE
Employees
13,000
Headquarters
Vaughan, Canada
Website
Bausch + Lomb Metrics
BasicAdvanced
$5.7bn
-
-$0.62
0.61
-
Price and volume
Market cap
$5.7bn
Beta
0.61
52-week high
$18.92
52-week low
$10.83
Average daily volume
433k
Financial strength
Current ratio
1.551
Quick ratio
0.836
Long term debt to equity
79.276
Total debt to equity
80.457
Interest coverage (TTM)
0.45%
Profitability
EBITDA (TTM)
724.25
Gross margin (TTM)
59.81%
Net profit margin (TTM)
-7.06%
Operating margin (TTM)
5.84%
Effective tax rate (TTM)
-4.98%
Revenue per employee (TTM)
$400,000
Management effectiveness
Return on assets (TTM)
0.85%
Return on equity (TTM)
-5.39%
Valuation
Price to revenue (TTM)
1.082
Price to book
0.87
Price to tangible book (TTM)
-3.54
Price to free cash flow (TTM)
-85.234
Free cash flow yield (TTM)
-1.17%
Free cash flow per share (TTM)
-0.187
Growth
Revenue change (TTM)
7.85%
Earnings per share change (TTM)
-39.53%
3-year revenue growth (CAGR)
10.62%
3-year earnings per share growth (CAGR)
27.88%
Bausch + Lomb News
AllArticlesVideos
Bausch + Lomb Releases 2025 Sustainability Impact Report
Business Wire·1 week ago
Bausch + Lomb Reports Nearly 725,000 Pounds of Contact Lens, Lens Care and Eye Care Materials Collected and Recycled Through ONE By ONE Recycling Program
Business Wire·2 weeks ago
Bausch + Lomb Announces New Scientific Data, Educational Events at the American Society of Cataract and Refractive Surgery Annual Meeting
Business Wire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bausch + Lomb stock?
Bausch + Lomb (BLCO) has a market cap of $5.7B as of May 01, 2026.
What is the P/E ratio for Bausch + Lomb stock?
The price to earnings (P/E) ratio for Bausch + Lomb (BLCO) stock is 0 as of May 01, 2026.
Does Bausch + Lomb stock pay dividends?
No, Bausch + Lomb (BLCO) stock does not pay dividends to its shareholders as of May 01, 2026.
When is the next Bausch + Lomb dividend payment date?
Bausch + Lomb (BLCO) stock does not pay dividends to its shareholders.
What is the beta indicator for Bausch + Lomb?
Bausch + Lomb (BLCO) has a beta rating of 0.61. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.